These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32496881)

  • 1. A systematic review of economic evaluations of treatment regimens in multiple myeloma.
    Asrar MM; Lad DP; Prinja S; Bansal D
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):799-809. PubMed ID: 32496881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
    Aguiar PM; Lima TM; Storpirtis S
    J Clin Pharm Ther; 2016 Apr; 41(2):189-97. PubMed ID: 27009796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology.
    Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA
    Eur J Cancer; 2011 Jul; 47(10):1458-67. PubMed ID: 21561761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
    Picot J; Cooper K; Bryant J; Clegg AJ
    Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update: health economics of managing multiple myeloma.
    Moeremans K; Annemans L
    Eur J Cancer; 2006 Jul; 42(11):1684-91. PubMed ID: 16781867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example.
    Rochau U; Jahn B; Qerimi V; Burger EA; Kurzthaler C; Kluibenschaedl M; Willenbacher E; Gastl G; Willenbacher W; Siebert U
    Crit Rev Oncol Hematol; 2015 May; 94(2):164-78. PubMed ID: 25620327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.
    Gharaibeh M; Bootman JL; McBride A; Martin J; Abraham I
    Pharmacoeconomics; 2017 Jan; 35(1):83-95. PubMed ID: 27637757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of home-based, nurse-led health promotion for older people: a systematic review.
    Tappenden P; Campbell F; Rawdin A; Wong R; Kalita N
    Health Technol Assess; 2012; 16(20):1-72. PubMed ID: 22490205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality.
    Al Kadour A; Marridi WA; Al-Badriyeh D
    Value Health Reg Issues; 2018 Sep; 16():46-60. PubMed ID: 30144775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.
    Heather EM; Payne K; Harrison M; Symmons DP
    Pharmacoeconomics; 2014 Feb; 32(2):109-34. PubMed ID: 24338344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conducting systematic reviews of economic evaluations.
    Gomersall JS; Jadotte YT; Xue Y; Lockwood S; Riddle D; Preda A
    Int J Evid Based Healthc; 2015 Sep; 13(3):170-8. PubMed ID: 26288063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
    Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD004626. PubMed ID: 23076906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.
    Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):839-54. PubMed ID: 22716498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models.
    Freitag A; Sarri G; Ta A; Gurskyte L; Cherepanov D; Hernandez LG
    Pharmacoeconomics; 2024 Sep; 42(9):955-1002. PubMed ID: 38918342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
    Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
    Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of open transforaminal lumbar interbody fusion (OTLIF) versus minimally invasive transforaminal lumbar interbody fusion (MITLIF): a systematic review and meta-analysis.
    Droeghaag R; Hermans SMM; Caelers IJMH; Evers SMAA; van Hemert WLW; van Santbrink H
    Spine J; 2021 Jun; 21(6):945-954. PubMed ID: 33493680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.